Research reveals diagnostic biomarker for STB linked to inflammatory response and demethylation, suggesting a therapeutic approach targeting ALKBH5.
miR-221-3p may serve as a potential diagnostic biomarker for STB. ALKBH5 upregulation promotes STB progression by inhibiting miR-221-3p maturation via m6A demethylation, which enhances the inflammatory response. Targeting the ALKBH5/miR-221-3p axis may offer a novel therapeutic approach for STB.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: